ClinicalTrials.gg
TerminatedNCT00485589FILMUpdated Nov 3, 2020Results posted

A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)

A Phase 3 interventional study of Methotrexate and Ocrelizumab in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-03.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Why this study was terminated
Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
613
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
10th of 113
613 · median 130
Started
2007
with 8 others
Phase 3
47 of 113
1 open now
Registered
21st of 113
by date
Lead sponsor
4 of 113
Genentech, Inc.

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 10th largest by enrollment, is one of 9 that started in 2007, is one of 47 in phase 3, and was the 21st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who are naive to methotrexate. Patients will be randomized to receive placebo, ocrelizumab 200mg i.v. or ocrelizumab 500mg i.v. on Days 1 and 15. Repeat courses of i.v. treatment will be administered at weeks 24, 52 and 76. All patients will receive concomitant methotrexate (7.5 mg escalating to 20mg p.o. weekly). The anticipated time on study treatment is 2+ years, and the target sample size is 500+ individuals.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • FILM
  • RA
  • anti-CD20
  • CD20
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18
  • Rheumatoid arthritis for 3 months-5 years
  • Naive to methotrexate
  • If receiving or NSAIDs, must be on a stable dose for 4 weeks prior to baseline

Exclusion criteria

Exclusion criteria:

  • Rheumatic disease or inflammatory joint disease other than RA
  • Prior receipt of any biologic therapy for RA
  • Concurrent treatment with any DMARD
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
613 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, 76, and 78. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.

    Drug: Placebo

  • Experimental
    Ocrelizumab 200 mg

    Participants received ocrelizumab 200 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54 and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.

    Drug: Methotrexate · Drug: Ocrelizumab

  • Experimental
    Ocrelizumab 500 mg

    Participants received ocrelizumab 500 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.

    Drug: Methotrexate · Drug: Ocrelizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Modified Total Sharp Score (mTSS) at Week 52

    The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Percentage of Participants Without Radiographic Progression (RP) at Week 52

    RP was defined as a change from Baseline in the modified Total Sharp Score (mTSS) ≤ 0. The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.

    Time frame: Week 52

  2. Percentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52

    Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "none" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum" \[maximum arthritis disease activity\]; patient assessment of pain in the previous 24 hours on a VAS (extreme left end of the line "none" and the extreme right end "unbearable"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.

    Time frame: Baseline to Week 52

  3. Percentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52

    A participant was in DAS28 remission if their DAS28 score \< 2.6). The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score indicates more disease activity.

    Time frame: Week 24 and Week 52

07

Results

Posted Nov 3, 2020
Limitations and caveats
The study was terminated prematurely by the sponsors before all patients could reach the time point for primary analysis at Week 104. No patient received any further infusions of study medication.

Participant flow

Participant flow — Overall Study
MilestonePlaceboOcrelizumab 200 mgOcrelizumab 500 mg
Started210200203
Completed183180185
Not completed272018
Withdrew: Death220
Withdrew: Failure to return651
Withdrew: Protocol violation100
Withdrew: Violation of selection criteria at entry031
Withdrew: Administrative/other121
Withdrew: Insufficient therapeutic response1031
Withdrew: Refused treatment/did not cooperate102
Withdrew: Withdrawal by subject322
Withdrew: Adverse event3310

Outcome measures

PrimaryChange From Baseline in the Modified Total Sharp Score (mTSS) at Week 52

The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.

Time frame:
Baseline to Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Modified Total Sharp Score (mTSS) at Week 52
Units on a scalePlaceboOcrelizumab 200 mgOcrelizumab 500 mg
Change From Baseline in the Modified Total Sharp Score (mTSS) at Week 521.59 ± 4.8150.66 ± 4.5090.27 ± 2.908
Statistical analysis
  • Placebo vs Ocrelizumab 200 mg · Van Elteren's test · p = 0.001
  • Placebo vs Ocrelizumab 500 mg · Van Elteren's test · p = 0.0033
SecondaryPercentage of Participants Without Radiographic Progression (RP) at Week 52

RP was defined as a change from Baseline in the modified Total Sharp Score (mTSS) ≤ 0. The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Without Radiographic Progression (RP) at Week 52
Percentage of participantsPlaceboOcrelizumab 200 mgOcrelizumab 500 mg
Percentage of Participants Without Radiographic Progression (RP) at Week 5251 (44 to 58)66.3 (59.5 to 73.1)68.8 (62.2 to 75.3)
SecondaryPercentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52

Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line "none" \[symptom-free and no arthritis symptoms\] and the extreme right end "maximum" \[maximum arthritis disease activity\]; patient assessment of pain in the previous 24 hours on a VAS (extreme left end of the line "none" and the extreme right end "unbearable"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Week 52
Percentage of participantsPlaceboOcrelizumab 200 mgOcrelizumab 500 mg
ACR2057.5 (50.8 to 64.2)73 (66.7 to 79.2)71 (64.7 to 77.3)
ACR5039.6 (33 to 46.3)60.7 (53.9 to 67.6)54.5 (47.6 to 61.4)
ACR7020.3 (14.8 to 25.8)38.3 (31.5 to 45.1)38 (31.3 to 44.7)
SecondaryPercentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52

A participant was in DAS28 remission if their DAS28 score \< 2.6). The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \[symptom-free and no arthritis symptoms\], right end = maximum disease activity \[maximum arthritis disease activity\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score indicates more disease activity.

Time frame:
Week 24 and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants in Disease Activity Score 28 (DAS28) Remission at Weeks 24 and 52
Percentage of participantsPlaceboOcrelizumab 200 mgOcrelizumab 500 mg
Week 249.7 (5.6 to 13.7)19.9 (14.3 to 25.5)18 (12.7 to 23.3)
Week 527.2 (3.7 to 10.8)27 (20.8 to 33.3)28 (21.8 to 34.2)

Adverse events

Collected over Baseline up to 30 months.. Non-serious events are listed at a 0.05% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Treatment Period0/207 (0%)22/207 (10.6%)128/207 (61.8%)
Placebo/Ocrelizumab 500 mg - Treatment Period0/10 (0%)0/10 (0%)4/10 (40%)
Ocrelizumab 200 mg - Treatment Period0/196 (0%)21/196 (10.7%)135/196 (68.9%)
Ocrelizumab 200 mg/Ocrelizumab 500 mg - Treatment Period0/12 (0%)1/12 (8.3%)6/12 (50%)
Ocrelizumab 500 mg - Treatment Period0/202 (0%)31/202 (15.3%)144/202 (71.3%)
Ocrelizumab 500 mg/Ocrelizumab 500 mg - Treatment Period0/6 (0%)0/6 (0%)3/6 (50%)
Placebo - Safety Follow-up Period2/187 (1.1%)11/187 (5.9%)35/187 (18.7%)
Placebo/Ocrelizumab 500 mg - Safety Follow-up Period0/9 (0%)2/9 (22.2%)3/9 (33.3%)
Ocrelizumab 200 mg - Safety Follow-up Period2/177 (1.1%)2/177 (1.1%)32/177 (18.1%)
Ocrelizumab 200 mg/Ocrelizumab 500 Mg-safety Follow-up Period0/11 (0%)0/11 (0%)3/11 (27.3%)
Ocrelizumab 500 mg - Safety Follow-up Period1/185 (0.5%)4/185 (2.2%)49/185 (26.5%)
Ocrelizumab 500 mg/Ocrelizumab 500 mg -Safety Follow-up Period0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 98
Most frequent serious events
EventPlacebo - Treatment PeriodPlacebo/Ocrelizumab 500 mg - Treatment PeriodOcrelizumab 200 mg - Treatment PeriodOcrelizumab 200 mg/Ocrelizumab 500 mg - Treatment PeriodOcrelizumab 500 mg - Treatment PeriodOcrelizumab 500 mg/Ocrelizumab 500 mg - Treatment PeriodPlacebo - Safety Follow-up PeriodPlacebo/Ocrelizumab 500 mg - Safety Follow-up PeriodOcrelizumab 200 mg - Safety Follow-up PeriodOcrelizumab 200 mg/Ocrelizumab 500 Mg-safety Follow-up PeriodOcrelizumab 500 mg - Safety Follow-up PeriodOcrelizumab 500 mg/Ocrelizumab 500 mg -Safety Follow-up Period
Hepatic cirrhosisHepatobiliary disorders0/2070/100/1960/120/2020/60/1871/90/1770/110/1850/6
AngioedemaSkin and subcutaneous tissue disorders0/2070/100/1960/120/2020/60/1871/90/1770/110/1850/6
PneumoniaInfections and infestations3/2070/100/1960/122/2020/61/1871/92/1770/111/1850/6
Abdominal wall infectionInfections and infestations0/2070/100/1961/120/2020/60/1870/90/1770/110/1850/6
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/2070/100/1960/123/2020/60/1870/90/1770/110/1850/6
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/2070/102/1960/121/2020/61/1870/92/1770/110/1850/6
OsteoarthritisMusculoskeletal and connective tissue disorders0/2070/102/1960/121/2020/60/1870/90/1770/111/1850/6
CholelithiasisHepatobiliary disorders0/2070/100/1960/122/2020/60/1870/90/1770/110/1850/6
Urinary tract infectionInfections and infestations0/2070/101/1960/122/2020/60/1870/90/1770/111/1850/6
Inguinal herniaGastrointestinal disorders2/2070/100/1960/120/2020/60/1870/90/1770/110/1850/6
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPlacebo - Treatment PeriodPlacebo/Ocrelizumab 500 mg - Treatment PeriodOcrelizumab 200 mg - Treatment PeriodOcrelizumab 200 mg/Ocrelizumab 500 mg - Treatment PeriodOcrelizumab 500 mg - Treatment PeriodOcrelizumab 500 mg/Ocrelizumab 500 mg - Treatment PeriodPlacebo - Safety Follow-up PeriodPlacebo/Ocrelizumab 500 mg - Safety Follow-up PeriodOcrelizumab 200 mg - Safety Follow-up PeriodOcrelizumab 200 mg/Ocrelizumab 500 Mg-safety Follow-up PeriodOcrelizumab 500 mg - Safety Follow-up PeriodOcrelizumab 500 mg/Ocrelizumab 500 mg -Safety Follow-up Period
Infusion related reactionInjury, poisoning and procedural complications21/2074/1056/1960/1264/2021/60/1870/90/1770/110/1850/6
Upper respiratory tract infectionInfections and infestations36/2070/1031/1960/1223/2021/67/1871/93/1772/117/1850/6
Bunion operationSurgical and medical procedures0/2070/100/1960/120/2020/60/1870/90/1770/110/1851/6
OedemaGeneral disorders2/2070/100/1960/120/2021/60/1870/90/1770/110/1850/6
Sinusitis noninfectiveRespiratory, thoracic and mediastinal disorders0/2070/100/1960/120/2020/60/1870/90/1770/110/1851/6
Dermatitis contactSkin and subcutaneous tissue disorders0/2070/100/1960/120/2020/62/1870/90/1770/110/1851/6
Vitamin D deficiencyMetabolism and nutrition disorders0/2070/100/1960/120/2020/60/1870/90/1770/111/1851/6
DyslipidaemiaMetabolism and nutrition disorders0/2070/100/1960/120/2020/60/1870/91/1770/111/1851/6
CystitisInfections and infestations3/2070/104/1960/124/2021/61/1870/91/1770/110/1850/6
Drug-induced liver injuryHepatobiliary disorders18/2070/1028/1960/1227/2020/60/1870/90/1770/110/1850/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboOcrelizumab 200 mgOcrelizumab 500 mgTotal
Mean49.2 ± 12.4350.8 ± 13.1748.6 ± 12.2949.5 ± 12.66
Sex/Gender, Customized
Sex/Gender, Customized(Participants)PlaceboOcrelizumab 200 mgOcrelizumab 500 mgTotal
Female153154161468
Male544241137
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Emery P, Rigby W, Tak PP, Dorner T, Olech E, Martin C, Millar L, Travers H, Fisheleva E. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014 Feb 3;9(2):e87379. doi: 10.1371/journal.pone.0087379. eCollection 2014. PubMed 24498318 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2007 to primary completion in Jan 2010, 31 months.

Results were first posted in Nov 2020, 10 years 9 months after primary completion. A results delay was requested in Jun 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2007
First posted
Jun 13, 2007
StartActual
Jun 11, 2007
Primary completionActual
Jan 29, 2010
CompletionActual
Aug 29, 2013
Results delay requested
Jun 28, 2013
Results first posted
Nov 3, 2020
Last update
Nov 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00485589
Lead sponsor
Genentech, Inc.
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
Jun 13, 2007
Start date
Jun 11, 2007
Primary completion
Jan 29, 2010
Completion
Aug 29, 2013
Results posted
Nov 3, 2020
Last update
Nov 3, 2020

Study contacts

Wolfgang Dummer, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Ocrelizumab

Start the discussion